. Author manuscript; available in PMC: 2017 Mar 27.

Published in final edited form as: Brain. 2014 Sep 10;137(Pt 11):2909–2915. doi: 10.1093/brain/awu255

Table 1. Testing of CSF for amyloid-β seeding capacity.

		Sex	Mean age	Amyloid-β₄₂	Total amyloid-β	Seeding activity
Fraction		(m/f)	(years)	(pg/ml)	(pg/ml)	Incubation	Induction^*
Alzheimer’s disease brain SN	n = 3	2/1	78	73 ± 18	512 ± 193	6–8 months	12/12
Alzheimer’s disease CSF	n = 8	4/4	66	514 ± 199	8644 ± 1514	6–8 months	0/27
Control CSF	n = 6	3/3	63	717 ± 111	6834 ± 1835	6–8 months	0/26
CSF APP transgenic	n = 2	2/-	2	2750 ± 323	31455 ± 2508	8 months	0/3
CSF wild-type	n = 2	2/-	2	n.d.	n.d.	8 months	0/1

The total number of animals with induced amyloid-β deposition/total number of animals tested is indicated (for more detailed information about subjects, clinical diagnosis and biochemical measurements see Supplementary Table 1).

SN = supernatant; m = male; f = female; n.d. = not detected.